ViGeneron and Daiichi Sankyo to Develop a Novel Gene Therapy for Prevalent...
ViGeneron GmbH, a next-generation gene therapy company, has announced a follow-on collaboration with Daiichi Sankyo Company, Limited to utilize ViGeneron’s novel engineered recombinant adeno-associated...
View ArticleBasilea announces licensing of a novel first-in-class antifungal program from...
Basilea Pharmaceutica Ltd has entered into a licensing agreement with the U.S.-based company, Fox Chase Chemical Diversity Center, Inc. (FCCDC), for a preclinical program on novel first-in-class broad...
View ArticleNovartis Announces Positive Phase III Results for its ESCC Drug
Novartis has announced positive topline results from an interim analysis of the Phase III RATIONALE 306 study, which showed anti-PD-1 immune checkpoint inhibitor tislelizumab plus chemotherapy...
View ArticleVifor-Cara Therapeutics’s Kapruvia Approved for Treatment of...
Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics have announced that the European Commission has granted marketing authorization to Kapruvia (difelikefalin) for the treatment of...
View ArticleFDA Approves BMS’s Camzyos for the Treatment of Adults With Symptomatic New...
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of adults with...
View ArticleTeva in another settlement over price fixing charges in U.S.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has reached a deferred prosecution agreement (DPA) with the U.S. Department of Justice (DOJ) to settle the criminal...
View ArticleNew Safety Data Suggests Esketamine Nasal Spray Spravato is more tolerable...
The new safety data is from the ESCAPE-TRD Phase 3b study, which showed esketamine NS demonstrated a significant increase in…
View ArticleCellectis and Imagine Institute post successful demonstration of PIK3CD gene...
Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the…
View ArticleInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with...
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall…
View ArticleProKidney Announces Pricing of its Upsized $130 Million Public Offering of...
ProKidney Corp., a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced the pricing of an…
View ArticlePress Release: ISTH: Sanofi advances leadership in hemophilia with new data...
Sanofi will present new data from its hemophilia portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place June 22-26, 2024, in Bangkok, Thailand.
View ArticleIdorsia’s treatment for chronic insomnia wins Prix Galien Suisse 2024
Idorsia said Friday its novel treatment for chronic insomnia has been awarded the Prix Galien Suisse 2024 innovation prize in…
View ArticleAltimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity...
Full analysis of body composition data showed class-leading lean mass preservation with 21.9% of weight loss attributable to lean mass and 78.1% attributable to fat
View ArticleBioVie Inc. Announces Proposed Public Offering
BioVie, a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders,…
View ArticleDBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
French DBV Technologies has completed screening for the VITESSE phase 3 clinical trial In Q3 2024, exceeding its recruitment goal and successfully closed the screening process for the VITESSE Phase 3...
View ArticleBrenntag celebrates the company’s 150th anniversary in Essen, Germany
Brenntag, the global market leader in chemicals and ingredients distribution, held a celebration to mark its 150-year anniversary yesterday in Essen, Germany, where the DAX40 company is headquartered.
View Article